COPD

Pulmonary rehabilitation can offer many of the same ideas to patients that cognitive behavioral therapy (CBT) can, even inadvertently, the study authors said.

Exacerbations of patients with chronic obstructive pulmonary disorder (COPD) can be costly if they are frequent, and early detection programs for COPD may help offset these costs, according to research from 2 studies presented at the 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) virtual conference.

Chronic breathlessness not only affects patients with chronic obstructive pulmonary disease (COPD) but also their caregivers, who are mostly women, according to a recent review.

Although pulmonary rehabilitation for chronic obstructive pulmonary disease (COPD) is linked to better survival, a large study of fee-for-service (FFS) Medicare patients show it is underused, with less than 2% of those studied taking part in a 3-month program.

The patients selected for bronchoscopic lung volume reduction were younger compared with those who were not, the investigators said.

Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic obstructive pulmonary disease (COPD) in the US healthcare system.

Compared with patients with low stress, patients with chronic obstructive pulmonary disease (COPD) and high stress had doubled odds of using acute care services, a new study found.

High-flow nasal therapy (HFNT), often used for stable patients, can reduce hospital readmission for acute exacerbations for chronic obstructive pulmonary disease (COPD).

Chronic obstructive pulmonary disease (COPD) is not an independent risk factor for metabolic disorders, according to a recent report.

Prevention of acute kidney injury should be top of mind when discharging patients with chronic obstructive pulmonary disease (COPD) from the hospital, according to a recent study.

Over a 2-year study period, some patients with chronic obstructive pulmonary disease (COPD) were able to reverse or improve their frailty status, investigators found. The condition is present in close to one-third of patients with COPD.

A large-scale study reports that patients with chronic obstructive pulmonary disease (COPD)—even if they never smoked—have a 2.6 times greater incidence of developing lung cancer compared with those who had neither COPD or a history of smoking.

Claims data analysis showed that 60% of patients with chronic obstructive pulmonary disease (COPD) receiving triple therapy had no evidence of exacerbation or only 1 exacerbation not resulting in hospitalization.

Thomas C. Corbridge, MD, FCCP, is a GSK medical expert and an emeritus physician and adjunct professor of medicine at Northwestern University, Feinberg School of Medicine in Chicago, Illinois. Dr. Corbridge received his medical degree from the University of Chicago Pritzker School of Medicine and has been in practice for over 30 years. Dr. Corbridge specializes in pulmonary and critical care medicine and is experienced in asthma, chronic obstructive pulmonary disease and general pulmonology.

This study examined risk of exacerbation using a new predictive tool called COPD treatment ratio.

Chronic obstructive pulmonary disease (COPD) may incur huge medical expenses, resulting in a heavy socioeconomic burden. A recent study sought to predict the level of healthcare utilization resources.

Amazon has decided to suspend nonessential item shipments; study results show patients with chronic obstructive pulmonary disease (COPD) benefited from a fluticasone furoate/umeclidinium/vilanterol combination inhaler; disruptions from the coronavirus now extend to proposed mergers among industry giants.

Platelet indices may be altered in chronic obstructive pulmonary disease and therefore act as a valuable diagnostic marker, according to research.

In 11 patients with severe cases of COPD and hypercapnic respiratory failure, lung volume reduction coil treatment was associated with significant decreases in carbon dioxide levels and improvement in quality-of-life and respiratory function tests, according to study findings.

The implementation of integrated care conferences, a daily meeting for providers to share information, can significantly reduce the length of hospital stays in patients with chronic obstructive pulmonary disease (COPD) by up to 67%, according to study findings.

Researchers recently examined 18 diseases represented by outpatient visits to a hospital in Taiwan to determine patterns of the effect of air pollution on different organs and found evidence that concurrent occurrences of diseases show that the immune system tries to create protective defenses.

Statin use was linked with a significant reduction in the risk of hospitalized exacerbations after an initial hospitalized exacerbation among patients with chronic obstructive pulmonary disease (COPD), including specified frequent exacerbators, according to study findings.

Improving relational coordination and reducing structural barriers to collaboration may enhance quality of care for chronic obstructive pulmonary disease (COPD) and other chronic conditions.

In-home noninvasive positive pressure ventilation via bilevel positive airway pressure devices exhibited lower risk of mortality, fewer patients with all-cause hospital admission, and less need for intubation, but had no significant difference in quality-of-life for patients with chronic obstructive pulmonary disease (COPD) and hypercapnia, according to study findings.